ClinicalTrials.gg
RecruitingNCT07843693Updated Sep 28, 2026

A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers

A Phase 1 interventional study of Upadacitinib and Tofacitinib in Healthy Volunteers, sponsored by AbbVie. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, open label, five arm study to evaluate the pharmacodynamic effects of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is >= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, Physical Exam (PE), vital signs, laboratory profile and a 12-lead (ECG).
  • A female must not be pregnant, or breastfeeding and is not considering becoming pregnant, cryopreserving her eggs or donating eggs during the study or for approximately 30 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, two or more prior episodes of herpes zoster, or one or more episodes of disseminated herpes zoster, one or more prior episodes of disseminated herpes simplex (including eczema herpeticum) or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].
  • Evidence of dysplasia or history of (including lymphoma and leukemia) other than successfully treated non- cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.
  • History or evidence of active tuberculosis (TB) disease or latent TB infection.
  • Participant has prior exposure to upadacitinib, tofacitinib or baricitinib within the past 90 days.
  • Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements on a regular basis.
  • Participant has used any medications, vitamins and/or herbal supplements within the 2-week period prior to study treatment administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm 1: Multiple doses of Upadacitinib

    Upadacitinib will be administered once daily

    Drug: Upadacitinib

  • Experimental
    Arm 2: Multiple doses of Tofacitinib

    Tofacitinib will be administered twice daily

    Drug: Tofacitinib

  • Experimental
    Arm 3: Multiple doses of Upadacitinib

    Upadacitinib will be administered once daily

    Drug: Upadacitinib

  • Experimental
    Arm 4: Multiple doses of Tofacitinib

    Tofacitinib will be administered twice daily

    Drug: Tofacitinib

  • Experimental
    Arm 5: Multiple doses of Baricitinib

    Baricitinib will be administered once daily

    Drug: Baricitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.

    Time frame: Up to 44 Days

  2. Average plasma concentration (Cavg) of Upadacitinib

    Cavg of Upadacitinib

    Time frame: Up to 44 Days

  3. Average plasma concentration (Cavg) of Tofacitinib

    Cavg of Tofacitinib

    Time frame: Up to 44 Days

  4. Average plasma concentration (Cavg) of Baricitinib

    Cavg of Baricitinib

    Time frame: Up to 44 Days

  5. Area under the concentration-time curve over 24 hours (AUC24) of Upadacitinib

    AUC24 of Upadacitinib

    Time frame: Up to 44 Days

  6. Area under the concentration-time curve over 24 hours (AUC24) of Tofacitinib

    AUC24 of Tofacitinib

    Time frame: Up to 44 Days

  7. Area under the concentration-time curve over 24 hours (AUC24) of Baricitinib

    AUC24 of Baricitinib

    Time frame: Up to 44 Days

  8. Maximum Observed Plasma Concentration (Cmax) of Upadacitinib

    Cmax of Upadacitinib

    Time frame: Up to 44 Days

  9. Maximum Observed Plasma Concentration (Cmax) of Tofacitinib

    Cmax of Tofacitinib

    Time frame: Up to 44 Days

  10. Maximum Observed Plasma Concentration (Cmax) of Baricitinib

    Cmax of Baricitinib

    Time frame: Up to 44 Days

07

Study locations

1 of 1 sites recruiting
  • Acpru /Id# 286751
    Grayslake, Illinois 60030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843693
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Aug 26, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 28, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Upadacitinib · Tofacitinib · Baricitinib

Start the discussion